Institution identification

Institution ID

3331114

Institution full name and acronym

Bordeaux University Hospital (CHU de Bordeaux)

Institution countries

France

Type of institution

Hospital/Clinic/Other health care facility

Institution role

Data provider
Researcher

Institution website

ENCePP partner

No
Institution description
The clinical data warehouse of the Bordeaux University Hospital comprises electronic health records on more than 2 million patients with data collection starting in 2005. The hospital complex is made up of three main sites and comprises a total of 3,041 beds (2021 figures). The database currently holds information about the person (demographics), visits (inpatient and outpatient), conditions and procedures (billing codes), drugs (outpatient prescriptions and inpatient orders and administrations), measurements (laboratory tests and vital signs) and dates of death (in or out-hospital death).
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

An Observational Registry Study To Evaluate The Use And Safety Of Cinacalcet Among Paediatric Patients With Secondary Hyperparathyroidism (20180204)
DARWIN EU® - Co-prescribing of endothelin receptor antagonists (ERAs) and phosphodiesterate-5 inhibitors (PDE-5is) in pulmonary arterial hypertension (PAH)
DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022
DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
Economic evaluation of Prostatic Urethral Lift (Urolift) (ECOLIFT)
Economic evaluation of robot-assisted laparoscopic radical prostatectomy vs conventional laparoscopic radical prostatectomy and open retropubic radical prostatectomy in prostate cancer: a real-life study based on the French National Healthcare Data System (SNDS). (ECOREPAR)
Impact of cardiovascular comorbidities on the effectiveness of bevacizumab in elderly patients with metastatic colorectal cancer (IRAZU)
Post-Authorisation Safety Study (PASS) of CLAIRYG® (Human normal immunoglobulin for intravenous use) in children under 12 years treated for primary immunodeficiency (PID) or immune thrombocytopenic purpura (ITP) (IGNGPASSP)